Key terms
About KROS
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KROS news
Mar 19
8:04am ET
Morphic appoints Cooper as Chief Medical Officer
Mar 19
1:37am ET
Strong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environment
Mar 13
7:35am ET
Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)
Mar 13
5:39am ET
Keros Therapeutics initiated with a Not Rated at Goldman Sachs
Mar 06
8:12am ET
Keros Therapeutics Updates Corporate Presentation Online
Mar 06
8:06am ET
Keros Therapeutics (KROS) Gets a Buy from Truist Financial
Mar 05
8:12am ET
Keros Therapeutics CMO Simon Cooper Resigns
Mar 05
8:12am ET
Keros Therapeutics CEO to Speak at Global Biopharma Conference
Mar 01
7:06am ET
Analysts’ Top Healthcare Picks: Xenon (XENE), Ascendis Pharma (ASND)
Mar 01
6:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)
Mar 01
12:57am ET
Buy Rating Affirmed for Keros Therapeutics Amid Positive Clinical Progress and Strategic Catalysts
Feb 29
10:55am ET
Optimistic Outlook for Keros Therapeutics’ Advancing Clinical Pipeline Justifies Buy Rating
Feb 29
6:48am ET
Buy Rating Justified by Keros Therapeutics’ Clinical Advancements and Strong Financial Position
Feb 29
6:20am ET
Keros Therapeutics price target raised to $77 from $60 at Wells Fargo
Feb 28
4:12pm ET
Keros Therapeutics reports Q4 EPS ($1.34) , consensus ($1.37)
Feb 26
11:45am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 26
4:55am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 21
12:10pm ET
Truist biotech analysts hold an analyst/industry conference call
Feb 21
7:12am ET
Keros Therapeutics initiated with an Outperform at William Blair
Jan 23
8:15am ET
Jefferies Analyst Issues Buy Rating for Keros Therapeutics, Citing Strong Pipeline and Financial Stability
Jan 09
7:37am ET
Piper Sandler Sticks to Its Buy Rating for Keros Therapeutics (KROS)
Jan 04
12:06am ET
Keros Therapeutics 3.5M share Spot Secondary priced at $40.00
Jan 03
7:45pm ET
Buy Rating on Keros Therapeutics Amid Strategic Shift to Obesity Treatments with Promising KER-065 Drug Candidate
Jan 03
6:00pm ET
Keros Therapeutics $120M Spot Secondary; price range $40.00-$41.26
Jan 03
4:06pm ET
Keros Therapeutics announces $120M common stock offering
Jan 03
8:10am ET
Keros Therapeutics to develop KER-065 for treatment of obesity
Jan 02
9:20am ET
Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Keros Therapeutics (KROS) and Xencor (XNCR)
Dec 31
5:10am ET
Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Keros Therapeutics (KROS) and Xencor (XNCR)
No recent news articles are available for KROS
No recent press releases are available for KROS
KROS Financials
Key terms
Ad Feedback
KROS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KROS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range